Editas Medicine, Inc. price and volume Combination chart with 2 data series. Chart represents Editas Medicine, Inc. price and volume over 1Y period The chart has 2 X axes displaying Time, and Time. The chart has 2 Y axes displaying symbol price, and symbol volume.. Mar 2025Jan 2025Nov ...
Editas Medicine, Inc. CRSP 41.57 -2.46% CRISPR Therapeutics AG BEAM 22.97 -4.33% Beam Therapeutics Inc. PACB 1.31 -1.88% Pacific Biosciences of California, Inc. NVTAQ 0.0003 0.00% Invitae Corporation Compare Similar to NTLA SymbolLast PriceChange RCUS 0 0.00% Arcus Biosciences, Inc. ...
시가총액 113,677,000 주요 거래소 NASDAQ Editas Medicine Inc 실적 희석 주당 순이익(TTM) -2.75 전년 대비 매출 증가율 -49% 전년 대비 수익 증가율 0% 이익률 0%
Editas is initiated with a sell rating and $20 price target at Goldman Sachs. EDIT Jim Cramer Stock Picks, Opinions and Predictions Jan 8, 2020 9:24 PM EST Resilient Bull: Cramer's 'Mad Money' Recap (Wednesday 1/8/20) Jim Cramer says this market environment is a strange merger of res...
Adaptive Biotechnologies started at overweight with $45 stock price target at J.P. Morgan Jul. 22, 2019 at 8:42 a.m. ET by Tomi Kilgore Adaptive Biotechnologies CEO Chad Robins on that crazy IPO and working with his older brother Jul. 1, 2019 at 10:28 a.m. ET by Sarah Toy ...
$3,606.34 +$32.96 (+0.9%) Closing Price on March 21, 2025 AZO Stock Chart and Intraday PriceAZO Stock DataAsset Type Stock Exchange NYSE Currency USD Country USA Sector TRADE & SERVICES Industry RETAIL-AUTO & HOME SUPPLY STORES Address 123 SOUTH FRONT ST, MEMPHIS, TN, US Fiscal Year End...
Find the latest TESARO, Inc., TSRO stock market data. Get a full understanding of how TESARO, Inc. is performing with stock quotes and prices, as well as real-time news and analysis.
Lexicon Pharma shares rally 48% premarket on positive trial of diabetes treatment Sep. 9, 2016 at 7:38 a.m. ET by Ciara Linnane Lexicon Pharmaceuticals started at buy with $21 stock price target at Citigroup Aug. 2, 2016 at 8:33 a.m. ET by Tomi Kilgore Lexicon's stock soars ...
1Y Price Target$10.00 Price Target Upside449.45% Upside Rating ConsensusModerate Buy Number of Analyst Covering1Show more Climb Bio News PremiumThe FlyClimb Bio to be added to Nasdaq Biotechnology Index 1M ago CLYM PremiumCompany AnnouncementsClimb Bio Inc. Shifts Focus to Immune-Mediated Diseases...
of the options above, you agree to the terms of use & privacy policy bull or bear, seeking alpha is there markets change, but our community always has the latest news, in-depth analysis, and powerful stock ratings. create free account celg celgene corporation stock price & overview follow ...